| Ytd | -21.85% | |
| 1y | -12.28% |
| Open | 60.67 | Prev Close | 60.77 | Low | 60.03 | High | 63.50 | Mkt Cap | 2.38B |
| Vol | 691.14K | Avg Vol | 471.18K | EPS | -6.58 | P/E | N/A | Forward P/E | -8.77 |
| Beta | 2.11 | Short Ratio | 14.68 | Inst. Own | 114.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 73.88 | 200-d Avg | 71.30 | 1yr Est | 103.17 |
IRON News
New York, New York--(Newsfile Corp. - October 7, 2026) - WHY: Rosen Law Firm, a global investor righ
New York, New York--(Newsfile Corp. - October 6, 2026) - WHY: Rosen Law Firm, a global investor righ
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
New York, New York--(Newsfile Corp. - October 4, 2026) - WHY: Rosen Law Firm, a global investor righ
New York, New York--(Newsfile Corp. - October 3, 2026) - WHY: Rosen Law Firm, a global investor righ
NEW YORK, Oct. 2, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues
New York, New York--(Newsfile Corp. - September 30, 2026) - WHY: Rosen Law Firm, a global investor r
New York, New York--(Newsfile Corp. - September 29, 2026) - WHY: Rosen Law Firm, a global investor r
NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
New York, New York--(Newsfile Corp. - September 27, 2026) - WHY: Rosen Law Firm, a global investor r
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Inv
NEW YORK, Sept. 26, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continue
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
New York, New York--(Newsfile Corp. - September 24, 2026) - WHY: Rosen Law Firm, a global investor r
New York, New York--(Newsfile Corp. - September 23, 2026) - WHY: Rosen Law Firm, a global investor r
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, con
Disc Medicine, Inc. (NASDAQ: IRON - Get Free Report) has received an average recommendation of "Mode
NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continue
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with severa
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and rai
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
Disc Medicine says Phase 2 RESTORE-PV data shows DISC-3405 reduces phlebotomy needs and controls hem
Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and m
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and ra
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove
HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.54) per share which beat the analyst co
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and ra
Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and m
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove
Consistent, substantial decreases in hepcidin reaching >75% reduction from baseline and correspon
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and ra
https://subscriber.politicopro.com/article/2026/05/makarys-time-atop-fda-over-tktk-named-acting-comm
https://www.cbsnews.com/news/trump-approves-plan-to-fire-fda-commissioner-marty-makary/?intcid=CNM-0
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.65) per share which beat the analyst co
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and rai
On February 26, 2026, the board of directors of Disc Medicine, Inc. (the "Company") approved
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and low
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.62) per share which beat the analyst co
Stifel analyst Stephen Willey maintains Disc Medicine (NASDAQ:IRON) with a Buy and lowers the pri
Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight
BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and lo
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and low
Disc Medicine stock plunged after an FDA rejection of its rare disease drug but rebounded as investo
Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on the discovery, development